As a young pathbreaking transformer in the Indian pharmaceutical landscape, Yogesh Agrawal, managing director of Ajanta Pharma Ltd., shares his desire to accelerate the company’s expansion in the US. Out of the total revenues of USD 308 million for FY17, the USA accounted for 28 million. He talks about the importance of having ground-breaking products that comply with international efficacy, safety and quality standards in order to build their trust and reputation and consolidate their presence in other emerging markets.
Mr. Agrawal, when thinking of India and the Indian pharmaceutical landscape, our global readers are used to names such as Lupin, Ranbaxy, Cadilla, Cipla etc. Yet, Ajanta is one of the biggest success stories of the past 15 years. Could you present the company to our international readers?
"We believe that India and the US are going to be future markets for us, because as the economy grows there will be more spend power and to this purpose we stay very committed."
